“ In FY26, our primary objectives include scaling our manufacturing capabilities, strengthening co-innovation initiatives, and expanding our product portfolio.”
“ In FY26, our primary objectives include scaling our manufacturing capabilities, strengthening co-innovation initiatives, and expanding our product portfolio.”
operational in just nine months, produces 30,000 single-use bags per month while maintaining global quality standards. Designed for scalability, it can triple its capacity to meet rising demand. This gives us a strong competitive edge, allowing us to offer just-in-time solutions, reduce costs, and eliminate long lead times— a challenge global suppliers often struggle with.
Further solidifying our competitive advantage, PharmNXT Biotech has established a strong foothold in 12 countries, including ASEAN, the U. S., and Europe, with offices in Singapore and South Korea and partnerships with leading players in the U. S. and Europe. We mix local manufacturing with global expertise, introducing advanced technology and scalable bioprocessing innovations to India. This combination helps us deliver high-quality, affordable, and fully integrated bioprocessing solutions. As a result, we have become the preferred choice for the biopharma companies.
BioTech
BIOVOICENEWS. COM 35